Vivos Inc Obtains Feedback from the FDA on Clinical Testing of RadioGel™
December 02, 2021 09:30 ET
|
Vivos Inc.
Richland WA, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), on November 30 Vivos Inc met with the Food and Drug Administration to obtain suggestions on improving the current draft of...
Vivos Inc Announces Johns Hopkins University (Veterinary Clinical Trials Network) is a New Regional Clinic for Isopet®
November 23, 2021 09:30 ET
|
Vivos Inc.
This replaces and corrects the press release from November 22. Johns Hopkins (VCTN) Veterinary Clinical Trials Network is our teaming partner not the Center for Image Guided Animal Therapy (CIGAT). ...
Vivos Inc Announces John Hopkins University as a New Regional Clinic for Isopet®
November 22, 2021 09:30 ET
|
Vivos Inc.
Richland WA, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc announced today that John Hopkins University Center for Image Guided Animal Therapy (CIGAT) is now an Isopet®...
Vivos Inc Signs a MOU for a New Regional Clinic in NY for IsoPet Therapy
October 18, 2021 09:30 ET
|
Vivos Inc.
Richland WA, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc announced today that it signed a Memorandum of Understanding with the Animal Hospital Surgical Center in East...
Vivos Inc Completes Certification Training Modules for Future IsoPet® Therapy Regional Clinics
September 22, 2021 09:30 ET
|
Vivos Inc.
Richland WA, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc working with FX Masse completed nine certification training modules that are part of the certification training...
Vivos Inc. Files Early Feasibility IDE Application with FDA for Radiogel™
September 20, 2021 09:30 ET
|
Vivos Inc.
Richland WA, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc. is pleased to announce that it has submitted the IDE, Investigational Device Exemption for The Early Feasibility...
Vivos Inc Receives Feedback from FDA on Breakthrough Designation Request
January 19, 2021 09:30 ET
|
Vivos Inc.
Richland WA, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Although we were unable to secure a Breakthrough Device Designation from the FDA, this was a well-designed process that...
Vivos Inc Completes Surrogate Lymph Node Testing Using Mouse Spleen Injections Demonstrating Uniform Perfusion and Stability
December 09, 2020 09:30 ET
|
Vivos Inc.
Richland WA, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc is pleased to announce today that it worked with Mayo Clinic doctors to design and then conduct tests on the...
Vivos Inc Extends it Intellectual Property Protection
December 01, 2020 09:30 ET
|
Vivos Inc.
Richland WA, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc announced today that it received the Patent Cooperation Treaty (PCT) International Search Report on our patent...
Vivos Inc. Treats Additional Patients at its Pilot Clinic
December 03, 2019 07:00 ET
|
Vivos Inc.
Richland WA, Dec. 03, 2019 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) today announced that two dogs with different cancer types were treated using Vivos Inc.’s Isopet® therapy on November 27 at...